Slide 1: Delivering in 2011
1 Delivering in 2011 June 2011
Slide 2: Forward-looking statements
Certain statements in this presentation may constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the operational and financial benefits of the business combination. Forward-looking information
Slide 3: Important Additional Information and Where to Find It
Important Additional Information and Where to Find It This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any juris
Slide 4: Alkermes and EDT: A Transformational Transaction
Alkermes and EDT: A Transformational Transaction Immediate profitability on a cash earnings basis and expanding Adjusted EBITDA margins Accretive transaction Growing revenues in excess of $450 million annually Driven by five major commercial products with long patent lives Incorporated in Ireland Ac
Slide 5: Combined commercial products overview
AMPYRA(r) (18% manufacturing and royalty rate) Treatment to improve walking in patients with multiple sclerosis (MS) Launched in U.S. in 2010, CHMP recommended approval in EU in May 2011 Patent life into 2026 VIVITROL(r) (Proprietary product) Once-monthly injectable medication for alcohol and opioid
Slide 6: AMPYRA
AMPYRA(r) Q1 '10 Q2 '10 Q3 '10 Q4 '10 Q1 '11 East 3.1 28 49.7 52.3 46.8 ($MM) End-Market Sales Treatment to improve walking in patients with multiple sclerosis (MS) Expands Alkermes' current therapeutic scope into MS Launched in U.S. in 2010, CHMP recommended approval in EU in May 2011 Marketed by A
Slide 7: VIVITROL
VIVITROL(r) ($MM) Once-monthly injectable medication for alcohol and opioid dependence Currently launching opioid indication Patent life into 2029 Proprietary product, currently marketed by Alkermes in U.S. FY09 FY10 LTM Revenue 8.9 20.7 26.5 Product Sales and Manufacturing Revenue 1. LTM (last twel
Slide 8: BYDUREON
BYDUREON(tm) First once-weekly GLP-1 for type 2 diabetes Long-acting version of Amylin's BYETTA(r) ($538 million LTM1 sales) CHMP recommendation for approval in Europe on 4/15/2011, anticipated launch 2H 2011 Planned U.S. resubmission 2H 2011 Patent life into 2025 Marketed by Eli Lilly and Amylin 8%
Slide 9: RISPERDAL CONSTA
RISPERDAL(r) CONSTA(r) Leading long-acting injectable antipsychotic for schizophrenia/bipolar I disorder Approved in over 90 countries, $1.5 billion in end- market sales Johnson & Johnson's 3rd largest pharmaceutical brand by product revenues in 2010 Patent life into 2023 in U.S., 2021 in Europe 10%
Slide 10: INVEGA SUSTENNA
INVEGA(r) SUSTENNA(r) Long-acting injectable antipsychotic for schizophrenia First monthly depot schizophrenia drug First commercialized NanoCrystal(r) depot product Approved in U.S. and Europe, recent UK launch Marketed by Johnson & Johnson Patent life into 2019 Tiered royalty rates on par with RIS
Slide 11: Combined Pipeline: CNS Focus
Schizophrenia ALKS 9070 RISPERDAL(r) CONSTA(r) INVEGA (r) SUSTENNA(r) Depression ALKS 5461 Reward Disorders ALKS 33 (binge eating) ALKS 33 (alcohol dependence) ALKS 5461 (cocaine addiction) VIVITROL(r) Pain Meloxicam IV ZX002 ALKS 36 OIC ALKS 37 MS AMPYRA(r) Combined Pipeline: CNS Focus 11
Slide 12: Strong Strategic Fit at the Right Time
Strong Strategic Fit at the Right Time EDT positioned for growth; AMPYRA(r) and INVEGA(r) SUSTENNA(r) at beginning of their growth trajectories Complementary world-class drug formulation and manufacturing expertise CNS-focused product portfolios Royalties from long-acting atypical antipsychotics now
Slide 13: EDT: Established Model for Profitability
EDT: Established Model for Profitability 40-year history with >35 approved drugs Commercial portfolio of 22 marketed drugs NanoCrystal(r) and Oral Controlled Release technologies Track record of innovation: AMPYRA(r), AVINZA(r), NAPRELAN(r) and VERELAN(r) Diversified revenue streams Royalties on com
Slide 14: Deep Product Portfolio with Diversified Revenue Streams
Deep Product Portfolio with Diversified Revenue Streams Products Mfg Rev Royalties Avinza(r) ? ? Luvox(r) CR ? ? Diltiazem(r) ? - Naprelan(r) ? - Rapamune(r) ? - Ritalin(r) LA / Focalin(r) XR ? ? Verelan(r) ? ? Zanaflex(r) Capsules ? ? Emend(r) ? ? Megace(r) ES - ? Skelaxin(r) - ? Tricor(r) 145 - ?
Slide 15: Key Transaction Terms
Key Transaction Terms Purchase Price Cash: $500 million Equity: 31.9 million shares (~25% of pro forma company) Funding Combination of cash on balance sheet and prepayable new term loan New debt of up to $450 million with secured financing from Morgan Stanley and HSBC Synergies ~$20 million synergie
Slide 16: Alkermes plc: Financial Strength
Alkermes plc: Financial Strength Trailing 12 months as of March 31, 2011 Pro forma revenues ~$450 million Pro forma Adjusted EBITDA ~$80 million Pro forma revenues Double-digit growth rates in FY'13 and beyond Pro forma Adjusted EBITDA margins Expected to be in range of 15-20% in FY'12 Expand to 30-
Slide 17: Meaningful Increase in Revenues & Profitability
($MM) Alkermes, Inc. Standalone Alkermes plc Pro Forma ($MM) Alkermes plc Pro Forma Alkermes, Inc. Standalone Meaningful Increase in Revenues & Profitability 17
Slide 18: Alkermes plc: Diversified Revenue Base
Alkermes plc: Diversified Revenue Base (based on CY '10) BYDUREON(tm) VIVITROL(r) RISPERDAL(r) CONSTA(r) MEGACE(r) SKELAXIN(r) Other TRICOR(r) LUVOX(r) ZANAFLEX(r) RAPAMUNE(r) DILTIAZAM(r) NAPRELAN(r) AVINZA(r) FOCALIN(r)/ RITALIN(r) VERELAN(r) AMPYRA(r) INVEGA(r) SUSTENNA(r) BYDUREON(tm) VIVITROL(r
Slide 19: Alkermes and EDT: A Transformational Transaction
Alkermes and EDT: A Transformational Transaction Immediate profitability on a cash earnings basis and expanding Adjusted EBITDA margins Accretive transaction Growing revenues in excess of $450 million annually Driven by five major commercial products with long patent lives Incorporated in Ireland Ac
Slide 20: www.alkermes.com
www.alkermes.com COPYRIGHT (c) 2011 ALKERMES, INC. 20